JP2021515032A5 - - Google Patents
Info
- Publication number
- JP2021515032A5 JP2021515032A5 JP2020566524A JP2020566524A JP2021515032A5 JP 2021515032 A5 JP2021515032 A5 JP 2021515032A5 JP 2020566524 A JP2020566524 A JP 2020566524A JP 2020566524 A JP2020566524 A JP 2020566524A JP 2021515032 A5 JP2021515032 A5 JP 2021515032A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cancer
- antibody
- combination drug
- drug according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023173684A JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862631771P | 2018-02-17 | 2018-02-17 | |
| US62/631,771 | 2018-02-17 | ||
| US201862757729P | 2018-11-08 | 2018-11-08 | |
| US62/757,729 | 2018-11-08 | ||
| PCT/US2019/018377 WO2019161320A1 (en) | 2018-02-17 | 2019-02-17 | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173684A Division JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021515032A JP2021515032A (ja) | 2021-06-17 |
| JP2021515032A5 true JP2021515032A5 (enExample) | 2022-03-09 |
Family
ID=67620025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566524A Pending JP2021515032A (ja) | 2018-02-17 | 2019-02-17 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
| JP2023173684A Pending JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023173684A Pending JP2024009886A (ja) | 2018-02-17 | 2023-10-05 | 好中球調節物質と免疫チェックポイントの調節物質の組み合わせを使用したがん処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200405719A1 (enExample) |
| EP (1) | EP3752528A4 (enExample) |
| JP (2) | JP2021515032A (enExample) |
| CN (1) | CN112424222A (enExample) |
| CA (1) | CA3091373A1 (enExample) |
| WO (1) | WO2019161320A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| CA3181336A1 (en) * | 2020-04-26 | 2021-11-04 | Apollomics Inc. | Novel pharmaceutical formulation for c-met inhibitor |
| EP4159238A4 (en) * | 2020-06-02 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY |
| CN113105436B (zh) * | 2021-04-20 | 2022-07-01 | 西格莱(苏州)生物医药有限公司 | 吡唑类化合物的制备方法及其中间体 |
| WO2023172629A2 (en) * | 2022-03-08 | 2023-09-14 | Brown University | Anticancer maleimide derivatives for use with immune checkpoint blockade |
| WO2025129332A1 (en) * | 2023-12-21 | 2025-06-26 | 11949098 Canada Inc. (Nuredco) C/O Jean I. Tchervenkov | Method of prognosis and monitoring of cancer patient and of determining immunological status of a subject |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101050829B1 (ko) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | 항 ｐｄ-1 항체 또는 항 ｐｄ-ｌ1 항체를 포함하는 항암제 |
| CN103122000B (zh) * | 2012-09-03 | 2013-12-25 | 中美冠科生物技术（太仓）有限公司 | 用作抗肿瘤药物的高选择性的c-Met激酶抑制剂 |
| MX2016012285A (es) * | 2014-03-24 | 2017-01-23 | Genentech Inc | Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf. |
| MX388181B (es) * | 2014-07-22 | 2025-03-19 | Cb Therapeutics Inc | Anticuerpos anti-pd-1. |
| JP6909153B2 (ja) * | 2014-08-05 | 2021-07-28 | アポロミクス インコーポレイテッド | 抗ｐｄ−ｌ１抗体 |
| KR20170066546A (ko) * | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| TWI695837B (zh) * | 2014-12-04 | 2020-06-11 | 比利時商健生藥品公司 | 作為激酶調節劑之三唑並嗒 |
| IL255312B (en) * | 2015-05-12 | 2022-08-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist |
| CA3000386A1 (en) * | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| RU2018125603A (ru) * | 2015-12-17 | 2020-01-21 | Новартис Аг | Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения |
| CA3091373A1 (en) * | 2018-02-17 | 2019-08-22 | Apollomics Inc. | Cancer treatment using combination of neutrophil modulator with modulator of immune checkpoint |
| EP4159238A4 (en) * | 2020-06-02 | 2024-08-07 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | COMBINED PHARMACEUTICAL COMPOSITION OF C-MET KINASE INHIBITOR AND ANTI-PD-L1 ANTIBODY |
-
2019
- 2019-02-17 CA CA3091373A patent/CA3091373A1/en active Pending
- 2019-02-17 WO PCT/US2019/018377 patent/WO2019161320A1/en not_active Ceased
- 2019-02-17 CN CN201980026429.9A patent/CN112424222A/zh active Pending
- 2019-02-17 EP EP19754620.3A patent/EP3752528A4/en not_active Withdrawn
- 2019-02-17 US US16/970,384 patent/US20200405719A1/en not_active Abandoned
- 2019-02-17 JP JP2020566524A patent/JP2021515032A/ja active Pending
-
2023
- 2023-10-05 JP JP2023173684A patent/JP2024009886A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2012515776A5 (enExample) | ||
| RU2013130250A (ru) | Замещенные пуриновые и 7-деазапуриновые соединения | |
| JP2016506958A5 (enExample) | ||
| JP2018502902A5 (enExample) | ||
| JP2021533135A5 (enExample) | ||
| JP2021532162A5 (enExample) | ||
| TR201809990T4 (en) | NEW COMPOSITIONS, USES AND METHODS FOR THEIR MAKING. | |
| RU2014140735A (ru) | ПРОИЗВОДНЫЕ ПИРАЗОЛО[1, 5-a]ПИРИМИДИНА, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ СОЕДИНЕНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2018530554A5 (enExample) | ||
| JP2015534574A5 (enExample) | ||
| JP2016508130A5 (enExample) | ||
| JP2015517574A5 (enExample) | ||
| RU2021102253A (ru) | Деструкторы белка mdm2 | |
| JP2013544846A5 (enExample) | ||
| JP2017510660A5 (enExample) | ||
| RU2018105614A (ru) | Производное 1,3,5-триазина и способ его применения | |
| EA201890094A1 (ru) | Производные полициклических амидов в качестве ингибиторов cdk9 | |
| RU2016135922A (ru) | Терапевтические соединения и композиции | |
| RU2014145121A (ru) | Пиримидиновые соединения для лечения злокачественной опухоли | |
| EA201490580A1 (ru) | Пирролбензодиазепины и их конъюгаты | |
| JP2016503414A5 (enExample) | ||
| JP2018511628A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| MX344276B (es) | Compuesto de piperidina novedoso o sal del mismo. |